{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:45:44Z","timestamp":1793256344630,"version":"4.5.0"},"reference-count":126,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,14]],"date-time":"2014-11-14T00:00:00Z","timestamp":1415923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AR054381"],"award-info":[{"award-number":["AR054381"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes & Diseases"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.gendis.2014.10.004","type":"journal-article","created":{"date-parts":[[2014,11,17]],"date-time":"2014-11-17T13:38:12Z","timestamp":1416231492000},"page":"13-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":295,"title":["Insulin-like growth factor (IGF) signaling in\u00a0tumorigenesis and the development of\u00a0cancer drug resistance"],"prefix":"10.1016","volume":"2","author":[{"given":"Sahitya K.","family":"Denduluri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olumuyiwa","family":"Idowu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengjian","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam K.","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jixing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianggong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hue H.","family":"Luu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gendis.2014.10.004_bib1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0304-3835(03)00159-9","article-title":"The insulin-like growth factor system and cancer","volume":"195","author":"LeRoith","year":"2003","journal-title":"Cancer Lett"},{"key":"10.1016\/j.gendis.2014.10.004_bib2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1096-6374(02)00017-5","article-title":"Control of cell survival by IGF signaling pathways","volume":"12","author":"Vincent","year":"2002","journal-title":"Growth Horm IGF Res: official journal of the Growth Hormone Research Society and the International IGF Research Society"},{"key":"10.1016\/j.gendis.2014.10.004_bib3","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1158\/1078-0432.CCR-09-2232","article-title":"Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy","volume":"16","author":"Zha","year":"2010","journal-title":"Clin Cancer Res: an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.gendis.2014.10.004_bib4","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/JME-11-0022","article-title":"Signalling by insulin and IGF receptors: supporting acts and new players","volume":"47","author":"Siddle","year":"2011","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.gendis.2014.10.004_bib5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1101\/gad.11.6.701","article-title":"The PI 3-kinase\/Akt signaling pathway delivers an anti-apoptotic signal","volume":"11","author":"Kennedy","year":"1997","journal-title":"Genes Dev"},{"key":"10.1016\/j.gendis.2014.10.004_bib6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nrm1837","article-title":"Critical nodes in signalling pathways: insights into insulin action","volume":"7","author":"Taniguchi","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.gendis.2014.10.004_bib7","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0006-2952(02)01135-8","article-title":"Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling","volume":"64","author":"Pouyssegur","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.gendis.2014.10.004_bib8","first-page":"761","article-title":"The insulin-like growth factor-binding protein (igfbp) superfamily","volume":"20","author":"Hwa","year":"1999","journal-title":"Endocr Rev"},{"key":"10.1016\/j.gendis.2014.10.004_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1535-7163.MCT-06-0080","article-title":"Disrupting insulin-like growth factor signaling as a potential cancer therapy","volume":"6","author":"Sachdev","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.gendis.2014.10.004_bib10","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrc1387","article-title":"Insulin-like growth factors and neoplasia","volume":"4","author":"Pollak","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.gendis.2014.10.004_bib11","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0140-6736(97)10384-1","article-title":"Circulating concentrations of insulin-like growth factor-I and risk of breast cancer","volume":"351","author":"Hankinson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.gendis.2014.10.004_bib12","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1093\/jnci\/91.7.620","article-title":"Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3","volume":"91","author":"Ma","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.gendis.2014.10.004_bib13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/0470869976.ch12","article-title":"IGF-1 and prostate cancer","volume":"262","author":"Roberts","year":"2004","journal-title":"Novartis Found Symp"},{"key":"10.1016\/j.gendis.2014.10.004_bib14","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/JTO.0b013e31818180f5","article-title":"The insulin-like growth factor pathway in lung cancer","volume":"3","author":"Dziadziuszko","year":"2008","journal-title":"J Thorac Oncol: official publication of the International Association for the Study of Lung Cancer"},{"key":"10.1016\/j.gendis.2014.10.004_bib15","doi-asserted-by":"crossref","first-page":"R321","DOI":"10.1530\/ERC-13-0231","article-title":"IGF2 and cancer","volume":"20","author":"Livingstone","year":"2013","journal-title":"Endocr Relat Cancer."},{"key":"10.1016\/j.gendis.2014.10.004_bib16","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1038\/onc.2011.97","article-title":"Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma","volume":"30","author":"Su","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.gendis.2014.10.004_bib17","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.canlet.2013.05.002","article-title":"IGFBP5 domains exert distinct inhibitory effects on the tumorigenicity and metastasis of human osteosarcoma","volume":"336","author":"Luther","year":"2013","journal-title":"Cancer Lett"},{"key":"10.1016\/j.gendis.2014.10.004_bib18","doi-asserted-by":"crossref","first-page":"242","DOI":"10.5732\/cjc.012.10263","article-title":"IGF-1R as an anti-cancer target\u2013trials and tribulations","volume":"32","author":"Chen","year":"2013","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.gendis.2014.10.004_bib19","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/441423a","article-title":"Signalling in cancer","volume":"441","author":"Eccleston","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.gendis.2014.10.004_bib20","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.2741\/2925","article-title":"The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance","volume":"13","author":"Casa","year":"2008","journal-title":"Front Biosci: a journal and virtual library"},{"key":"10.1016\/j.gendis.2014.10.004_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5339\/jlghs.2013.1","article-title":"Breast cancer and possible mechanisms of therapy resistance","volume":"2","author":"Florea","year":"2013","journal-title":"J Local Glob Health Sci"},{"key":"10.1016\/j.gendis.2014.10.004_bib22","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1158\/0008-5472.CAN-07-2707","article-title":"Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function","volume":"68","author":"Massarweh","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.gendis.2014.10.004_bib23","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/bcr2883","article-title":"Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK\/ERK and PI3K\/Akt signaling routes","volume":"13","author":"Zhang","year":"2011","journal-title":"Breast Cancer Res: BCR"},{"key":"10.1016\/j.gendis.2014.10.004_bib24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1023\/A:1009523501499","article-title":"Function of the IGF-I receptor in breast cancer","volume":"5","author":"Surmacz","year":"2000","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"10.1016\/j.gendis.2014.10.004_bib25","doi-asserted-by":"crossref","first-page":"R55","DOI":"10.1186\/bcr3449","article-title":"Autocrine IGF-I\/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation","volume":"15","author":"Fox","year":"2013","journal-title":"Breast Cancer Res: BCR"},{"key":"10.1016\/j.gendis.2014.10.004_bib26","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/tpj.2013.8","article-title":"Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen","volume":"14","author":"Winder","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.gendis.2014.10.004_bib27","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.canlet.2012.07.004","article-title":"IGFBP-3 sensitizes antiestrogen-resistant breast cancer cells through interaction with GRP78","volume":"325","author":"Li","year":"2012","journal-title":"Cancer Lett"},{"key":"10.1016\/j.gendis.2014.10.004_bib28","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1093\/jnci\/93.24.1852","article-title":"Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)","volume":"93","author":"Lu","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.gendis.2014.10.004_bib29","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1471-2407-14-134","article-title":"Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R","volume":"14","author":"Ye","year":"2014","journal-title":"BMC cancer"},{"key":"10.1016\/j.gendis.2014.10.004_bib30","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/bjc.2012.85","article-title":"Increased signalling of EGFR and IGF1R, and deregulation of PTEN\/PI3K\/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas","volume":"106","author":"Gallardo","year":"2012","journal-title":"B J Cancer"},{"key":"10.1016\/j.gendis.2014.10.004_bib31","first-page":"648965","article-title":"Deciphering the role of insulin-like growth factor-I receptor in trastuzumab resistance","volume":"2012","author":"Nahta","year":"2012","journal-title":"Chemother Res Pract"},{"key":"10.1016\/j.gendis.2014.10.004_bib32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.critrevonc.2012.02.010","article-title":"Targeting insulin-like growth factor in breast cancer therapeutics","volume":"84","author":"Karamouzis","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.gendis.2014.10.004_bib33","doi-asserted-by":"crossref","first-page":"9049","DOI":"10.18632\/oncotarget.2022","article-title":"Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer","volume":"5","author":"Liu","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.gendis.2014.10.004_bib34","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1158\/0008-5472.CAN-12-0684","article-title":"Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment","volume":"72","author":"Fagan","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.gendis.2014.10.004_bib35","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1615\/CritRevOncog.2014011455","article-title":"Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics","volume":"19","author":"Engelberth","year":"2014","journal-title":"Crit Rev Oncog"},{"key":"10.1016\/j.gendis.2014.10.004_bib36","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4252\/wjsc.v6.i4.441","article-title":"Ovarian cancer stem cells: can targeted therapy lead to improved progression-free survival?","volume":"6","author":"Walters Haygood","year":"2014","journal-title":"World J Stem Cells"},{"key":"10.1016\/j.gendis.2014.10.004_bib37","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.canlet.2014.08.023","article-title":"IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells","volume":"354","author":"Singh","year":"2014","journal-title":"Cancer Lett"},{"key":"10.1016\/j.gendis.2014.10.004_bib38","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1186\/1471-2407-13-549","article-title":"Identification of the IGF1\/PI3K\/NF kappaB\/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer","volume":"13","author":"Koti","year":"2013","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.gendis.2014.10.004_bib39","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1158\/1078-0432.CCR-13-3448","article-title":"Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy","volume":"20","author":"Beltran","year":"2014","journal-title":"Clin Cancer Res: an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.gendis.2014.10.004_bib40","doi-asserted-by":"crossref","first-page":"e100165","DOI":"10.1371\/journal.pone.0100165","article-title":"Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer","volume":"9","author":"Brouwer-Visser","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.gendis.2014.10.004_bib41","unstructured":"SEER Stat Fact Sheets: Prostate Cancer. http:\/\/seer.cancer.gov\/statfacts\/html\/prost.html."},{"key":"10.1016\/j.gendis.2014.10.004_bib42","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/jcb.20929","article-title":"Interaction of IGF signaling and the androgen receptor in prostate cancer progression","volume":"99","author":"Wu","year":"2006","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.gendis.2014.10.004_bib43","doi-asserted-by":"crossref","first-page":"8253","DOI":"10.1200\/JCO.2005.03.4777","article-title":"Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis","volume":"23","author":"Scher","year":"2005","journal-title":"J Clin Oncol: official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.gendis.2014.10.004_bib44","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/jcb.10653","article-title":"Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence","volume":"91","author":"Taplin","year":"2004","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.gendis.2014.10.004_bib45","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/pros.22744","article-title":"Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival","volume":"74","author":"Sharma","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.gendis.2014.10.004_bib46","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1530\/JOE-11-0240","article-title":"Global Igfbp1 deletion does not affect prostate cancer development in a c-Myc transgenic mouse model","volume":"211","author":"Gray","year":"2011","journal-title":"J Endocrinol"},{"key":"10.1016\/j.gendis.2014.10.004_bib47","doi-asserted-by":"crossref","first-page":"10553","DOI":"10.1073\/pnas.90.22.10553","article-title":"Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence","volume":"90","author":"Jones","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.gendis.2014.10.004_bib48","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1530\/ERC-13-0077","article-title":"Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2","volume":"20","author":"Biernacka","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.gendis.2014.10.004_bib49","first-page":"13","article-title":"Restoration of IGFBP-rP1 increases radiosensitivity and chemosensitivity in hormone-refractory human prostate cancer","volume":"62","author":"Seki","year":"2013","journal-title":"Hiroshima J Med Sci"},{"key":"10.1016\/j.gendis.2014.10.004_bib50","unstructured":"SEER Stat Fact Sheets: Lung and Bronchus Cancer."},{"key":"10.1016\/j.gendis.2014.10.004_bib51","first-page":"735","article-title":"The new concepts on overcoming drug resistance in lung cancer","volume":"8","author":"Zhang","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.gendis.2014.10.004_bib52","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s13402-013-0133-9","article-title":"Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer","volume":"36","author":"Peled","year":"2013","journal-title":"Cell Oncol (Dordr)"},{"key":"10.1016\/j.gendis.2014.10.004_bib53","first-page":"1705","article-title":"Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer","volume":"32","author":"Fidler","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.gendis.2014.10.004_bib54","doi-asserted-by":"crossref","first-page":"e86459","DOI":"10.1371\/journal.pone.0086459","article-title":"Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor","volume":"9","author":"Murakami","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.gendis.2014.10.004_bib55","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/ijc.28737","article-title":"The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor","volume":"135","author":"Suda","year":"2014","journal-title":"Int J Cancer. Journal international du cancer"},{"key":"10.1016\/j.gendis.2014.10.004_bib56","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1038\/srep02560","article-title":"IGF-1R\/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations","volume":"3","author":"Vazquez-Martin","year":"2013","journal-title":"Sci Rep"},{"key":"10.1016\/j.gendis.2014.10.004_bib57","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1158\/1078-0432.CCR-05-1846","article-title":"Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib","volume":"12","author":"Riely","year":"2006","journal-title":"Clin Cancer Res: an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.gendis.2014.10.004_bib58","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1158\/1078-0432.CCR-06-0462","article-title":"Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib","volume":"12","author":"Jackman","year":"2006","journal-title":"Clin Cancer Res: an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.gendis.2014.10.004_bib59","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3892\/etm.2011.324","article-title":"Combined inhibition of insulin-like growth factor-1 receptor enhances the effects of gefitinib in a human non-small cell lung cancer resistant cell line","volume":"2","author":"Qi","year":"2011","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.gendis.2014.10.004_bib60","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1002\/ijc.28594","article-title":"The PI3K\/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism","volume":"134","author":"Jeannot","year":"2014","journal-title":"Int J Cancer. Journal international du cancer"},{"key":"10.1016\/j.gendis.2014.10.004_bib61","doi-asserted-by":"crossref","first-page":"14670","DOI":"10.1074\/jbc.M110.193334","article-title":"The heparin-binding domain of IGFBP-2 has insulin-like growth factor binding-independent biologic activity in the growing skeleton","volume":"286","author":"Kawai","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.gendis.2014.10.004_bib62","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/10428190801896103","article-title":"Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib","volume":"49","author":"Hantschel","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.gendis.2014.10.004_bib63","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1158\/1535-7163.MCT-13-0233","article-title":"IGFBP2\/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells","volume":"12","author":"Lu","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.gendis.2014.10.004_bib64","first-page":"2609","article-title":"Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins","volume":"118","author":"Guix","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.gendis.2014.10.004_bib65","doi-asserted-by":"crossref","first-page":"e81393","DOI":"10.1371\/journal.pone.0081393","article-title":"Role of IGF-binding protein 3 in the resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase inhibitors","volume":"8","author":"Choi","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.gendis.2014.10.004_bib66","doi-asserted-by":"crossref","first-page":"G447","DOI":"10.1152\/ajpgi.2000.278.3.G447","article-title":"Cell-specific localization of insulin-like growth factor binding protein mRNAs in rat liver","volume":"278","author":"Zimmermann","year":"2000","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.gendis.2014.10.004_bib67","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/onc.2012.146","article-title":"IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR\/Akt pathway in non-small cell lung cancer","volume":"32","author":"Cortes-Sempere","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.gendis.2014.10.004_bib68","doi-asserted-by":"crossref","first-page":"e563","DOI":"10.1016\/j.ijrobp.2011.06.1999","article-title":"Role of insulin-like growth factor-1 signaling pathway in cisplatin-resistant lung cancer cells","volume":"82","author":"Sun","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.gendis.2014.10.004_bib69","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/carcin\/bgp179","article-title":"IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype","volume":"31","author":"Suzuki","year":"2010","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.gendis.2014.10.004_bib70","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4161\/cbt.13.3.18695","article-title":"Downregulation of insulin-like growth factor-binding protein 7 in cisplatin-resistant non-small cell lung cancer","volume":"13","author":"Okamura","year":"2012","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.gendis.2014.10.004_bib71","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cancergen.2012.10.009","article-title":"Genetics of adult glioma","volume":"205","author":"Goodenberger","year":"2012","journal-title":"Cancer Genet"},{"key":"10.1016\/j.gendis.2014.10.004_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5732\/cjc.013.10215","article-title":"High-grade gliomas: reality and hopes","volume":"33","author":"Mirimanoff","year":"2014","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.gendis.2014.10.004_bib73","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/stem.1328","article-title":"IGF1 receptor signaling regulates adaptive radioprotection in glioma stem cells","volume":"31","author":"Osuka","year":"2013","journal-title":"Stem cells (Dayton, Ohio)"},{"key":"10.1016\/j.gendis.2014.10.004_bib74","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/jcp.22433","article-title":"Hedgehog\/GLI1 regulates IGF dependent malignant behaviors in glioma stem cells","volume":"226","author":"Hsieh","year":"2011","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.gendis.2014.10.004_bib75","doi-asserted-by":"crossref","first-page":"e27053","DOI":"10.1371\/journal.pone.0027053","article-title":"Sensitization of glioma cells to tamoxifen-induced apoptosis by Pl3-kinase inhibitor through the GSK-3beta\/beta-catenin signaling pathway","volume":"6","author":"Li","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.gendis.2014.10.004_bib76","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11060-010-0374-7","article-title":"Wilms' tumor 1 silencing decreases the viability and chemoresistance of glioblastoma cells in\u00a0vitro: a potential role for IGF-1R de-repression","volume":"103","author":"Chen","year":"2011","journal-title":"J Neurooncol"},{"key":"10.1016\/j.gendis.2014.10.004_bib77","first-page":"4228","article-title":"Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling","volume":"59","author":"Fuller","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.gendis.2014.10.004_bib78","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/bjc.2014.435","article-title":"Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin beta1-ERK pathway","volume":"111","author":"Han","year":"2014","journal-title":"B J Cancer"},{"key":"10.1016\/j.gendis.2014.10.004_bib79","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/cancers5010048","article-title":"Gastric cancer: current status of diagnosis and treatment","volume":"5","author":"Takahashi","year":"2013","journal-title":"Cancers"},{"key":"10.1016\/j.gendis.2014.10.004_bib80","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.53738\/REVMED.2014.10.440.1582","article-title":"Pancreatic cancer in 2014: screening and epidemiology","volume":"10","author":"Bochatay","year":"2014","journal-title":"Revue medicale suisse"},{"key":"10.1016\/j.gendis.2014.10.004_bib81","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA: Cancer J Clin"},{"key":"10.1016\/j.gendis.2014.10.004_bib82","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrg1990","article-title":"The evolution of gene regulation by transcription factors and microRNAs","volume":"8","author":"Chen","year":"2007","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.gendis.2014.10.004_bib83","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1091\/mbc.E11-05-0456","article-title":"miR-503 represses CUG-binding protein 1 translation by recruiting CUGBP1 mRNA to processing bodies","volume":"23","author":"Cui","year":"2012","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.gendis.2014.10.004_bib84","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.3760\/cma.j.issn.0366-6999.20140318","article-title":"MiR-503 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R and BCL2","volume":"127","author":"Wang","year":"2014","journal-title":"Chin Med J"},{"key":"10.1016\/j.gendis.2014.10.004_bib85","doi-asserted-by":"crossref","first-page":"884","DOI":"10.2174\/1871520614666140528161318","article-title":"miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2","volume":"14","author":"Yang","year":"2014","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.gendis.2014.10.004_bib86","unstructured":"SEER Stat Fact Sheets: Colon and Rectum Cancer. http:\/\/seer.cancer.gov\/statfacts\/html\/colorect.html."},{"key":"10.1016\/j.gendis.2014.10.004_bib87","doi-asserted-by":"crossref","first-page":"F27","DOI":"10.1530\/ERC-11-0374","article-title":"Obesity, type 2 diabetes, and cancer: the insulin and IGF connection","volume":"19","author":"Cohen","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.gendis.2014.10.004_bib88","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3892\/ol.2013.1710","article-title":"Marginal effects of glucose, insulin and insulin-like growth factor on chemotherapy response in endothelial and colorectal cancer cells","volume":"7","author":"Volkova","year":"2014","journal-title":"Oncol Lett"},{"key":"10.1016\/j.gendis.2014.10.004_bib89","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrclinonc.2013.108","article-title":"Chemotherapy dosing in overweight and obese patients with cancer","volume":"10","author":"Lyman","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.gendis.2014.10.004_bib90","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/1389200043489199","article-title":"The MRP-related and BCRP\/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation","volume":"5","author":"Haimeur","year":"2004","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.gendis.2014.10.004_bib91","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/jcb.24080","article-title":"Inhibition of IGF-IR increases chemosensitivity in human colorectal cancer cells through MRP-2 promoter suppression","volume":"113","author":"Shen","year":"2012","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.gendis.2014.10.004_bib92","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s13277-013-1041-3","article-title":"Apicidin-resistant HA22T hepatocellular carcinoma cells massively promote pro-survival capability via IGF-IR\/PI3K\/Akt signaling pathway activation","volume":"35","author":"Hsu","year":"2014","journal-title":"Tumour Biol: the journal of the International Society for Oncodevelopmental Biology and Medicine"},{"key":"10.1016\/j.gendis.2014.10.004_bib93","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/hep.25745","article-title":"Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma","volume":"56","author":"Shan","year":"2012","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.gendis.2014.10.004_bib94","doi-asserted-by":"crossref","first-page":"e89686","DOI":"10.1371\/journal.pone.0089686","article-title":"Maintenance of stemness in oxaliplatin-resistant hepatocellular carcinoma is associated with increased autocrine of IGF1","volume":"9","author":"Bu","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.gendis.2014.10.004_bib95","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1007\/s10620-013-2673-2","article-title":"Insulin-like growth factor 1 receptor promotes the growth and chemoresistance of pancreatic cancer","volume":"58","author":"Tian","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gendis.2014.10.004_bib96","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrc2899","article-title":"KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma","volume":"10","author":"Morris","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.gendis.2014.10.004_bib97","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.canlet.2012.02.005","article-title":"K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas","volume":"322","author":"Wei","year":"2012","journal-title":"Cancer Lett"},{"key":"10.1016\/j.gendis.2014.10.004_bib98","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1046\/j.1523-5394.1999.76006.x","article-title":"Body image and quality of life after head and neck cancer surgery","volume":"7","author":"Dropkin","year":"1999","journal-title":"Cancer Pract"},{"key":"10.1016\/j.gendis.2014.10.004_bib99","doi-asserted-by":"crossref","unstructured":"So WKW, Chan RJ, Chan DNS, et\u00a0al. Quality-of-life among head and neck cancer survivors at one year after treatment \u2013 a systematic review. Eur J Cancer.48(15):2391\u20132408.","DOI":"10.1016\/j.ejca.2012.04.005"},{"key":"10.1016\/j.gendis.2014.10.004_bib100","first-page":"200","article-title":"Chemotherapeutic drug resistance in the management of head and neck cancer","volume":"250","author":"Bier","year":"1993","journal-title":"Eur Arch Otorhinolaryngol: official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS): affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery"},{"key":"10.1016\/j.gendis.2014.10.004_bib101","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.otpol.2013.10.010","article-title":"Cancer stem cells in head and neck squamous cell carcinoma","volume":"68","author":"Szafarowski","year":"2014","journal-title":"Otolaryngologia polska. The Polish Otolaryngology"},{"key":"10.1016\/j.gendis.2014.10.004_bib102","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1158\/1535-7163.MCT-11-0294","article-title":"Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells","volume":"10","author":"Jameson","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.gendis.2014.10.004_bib103","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10549-007-9763-9","article-title":"Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib (\u2018Iressa\u2019) response and resistance","volume":"111","author":"Knowlden","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.gendis.2014.10.004_bib104","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/hed.21478","article-title":"Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma","volume":"33","author":"Chung","year":"2011","journal-title":"Head Neck"},{"key":"10.1016\/j.gendis.2014.10.004_bib105","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ghir.2013.06.001","article-title":"Impact of targeting insulin-like growth factor signaling in head and neck cancers","volume":"23","author":"Limesand","year":"2013","journal-title":"Growth Horm IGF Res: official journal of the Growth Hormone Research Society and the International IGF Research Society"},{"key":"10.1016\/j.gendis.2014.10.004_bib106","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1634\/theoncologist.2008-0189","article-title":"The role of IGF-1R in pediatric malignancies","volume":"14","author":"Kim","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.gendis.2014.10.004_bib107","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11010-010-0453-2","article-title":"Lentivirus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells in\u00a0vitro and in\u00a0vivo","volume":"341","author":"Wang","year":"2010","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.gendis.2014.10.004_bib108","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11010-009-0064-y","article-title":"Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits growth, reduces invasion, and enhances radiosensitivity in human osteosarcoma cells","volume":"327","author":"Wang","year":"2009","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.gendis.2014.10.004_bib109","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3109\/07357907.2011.606252","article-title":"IGF1R-targeted therapy and its enhancement of doxorubicin chemosensitivity in human osteosarcoma cell lines","volume":"29","author":"Luk","year":"2011","journal-title":"Cancer Invest"},{"key":"10.1016\/j.gendis.2014.10.004_bib110","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1158\/1535-7163.MCT-09-0115","article-title":"Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines","volume":"8","author":"Duan","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.gendis.2014.10.004_bib111","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1096\/fj.08-114124","article-title":"IGF-independent effects of insulin-like growth factor binding protein-5 (Igfbp5) in\u00a0vivo","volume":"23","author":"Tripathi","year":"2009","journal-title":"FASEB J: official publication of the Federation of American Societies for Experimental Biology"},{"key":"10.1016\/j.gendis.2014.10.004_bib112","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ghir.2014.04.002","article-title":"Investigation of IGF2, Hedgehog and fusion gene expression profiles in pediatric sarcomas","volume":"24","author":"de Souza","year":"2014","journal-title":"Growth Horm IGF Res: official journal of the Growth Hormone Research Society and the International IGF Research Society"},{"key":"10.1016\/j.gendis.2014.10.004_bib113","first-page":"1","article-title":"Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma","author":"Kang","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.gendis.2014.10.004_bib114","first-page":"1","article-title":"IGF2BP1 controls cell death and drug resistance in rhabdomyosarcomas by regulating translation of cIAP1","author":"Faye","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.gendis.2014.10.004_bib115","first-page":"126","article-title":"Multidrug resistance in hematological malignancy. The journal of medical investigation","volume":"50","author":"Hirose","year":"2003","journal-title":"JMI"},{"key":"10.1016\/j.gendis.2014.10.004_bib116","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1634\/theoncologist.2007-0228","article-title":"Battling the hematological malignancies: the 200 years' War","volume":"13","author":"Lichtman","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.gendis.2014.10.004_bib117","first-page":"299","article-title":"Targeting the PI3K\/AKT\/mTOR signaling axis in children with hematologic malignancies","volume":"14","author":"Barrett","year":"2012","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.gendis.2014.10.004_bib118","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/jcmm.12162","article-title":"Co-targeting the PI3K\/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms","volume":"17","author":"Bartalucci","year":"2013","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.gendis.2014.10.004_bib119","first-page":"1","article-title":"Targeting PI3 kinase in cancer","author":"Bauer","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.gendis.2014.10.004_bib120","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fonc.2014.00108","article-title":"Targeting the PI3K\/mTOR pathway in pediatric hematologic malignancies","volume":"4","author":"Tasian","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.gendis.2014.10.004_bib121","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1182\/blood-2011-10-386789","article-title":"Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma","volume":"120","author":"Kuhn","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.gendis.2014.10.004_bib122","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1158\/1078-0432.CCR-12-3134","article-title":"Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors","volume":"19","author":"Tagoug","year":"2013","journal-title":"Clin Cancer Res: an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.gendis.2014.10.004_bib123","doi-asserted-by":"crossref","first-page":"e1300","DOI":"10.1038\/cddis.2014.268","article-title":"IGFBP7 induces apoptosis of acute myeloid leukemia cells and synergizes with chemotherapy in suppression of leukemia cell survival","volume":"5","author":"Verhagen","year":"2014","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.gendis.2014.10.004_bib124","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.leukres.2011.08.006","article-title":"High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia","volume":"35","author":"Kuhnl","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.gendis.2014.10.004_bib125","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/leu.2011.289","article-title":"IGFBP7 participates in the reciprocal interaction between acute lymphoblastic leukemia and BM stromal cells and in leukemia resistance to asparaginase","volume":"26","author":"Laranjeira","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.gendis.2014.10.004_bib126","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.ctrv.2014.07.004","article-title":"Can we unlock the potential of IGF-1R inhibition in cancer therapy?","volume":"40","author":"King","year":"2014","journal-title":"Cancer Treat Rev"}],"container-title":["Genes & Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304214000373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304214000373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T03:34:20Z","timestamp":1717558460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304214000373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":126,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S2352304214000373"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2014.10.004","relation":{},"ISSN":["2352-3042"],"issn-type":[{"value":"2352-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insulin-like growth factor (IGF) signaling in\u00a0tumorigenesis and the development of\u00a0cancer drug resistance","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2014.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Chongqing Medical University. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}